These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 34738163

  • 1. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T.
    Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
    [Abstract] [Full Text] [Related]

  • 2. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
    Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T.
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
    [Abstract] [Full Text] [Related]

  • 3. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
    Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, Yamamoto S, Takenobu T, Tomii K, Kawakita M, Katoh H, Ishikawa T, Yasui H, Hashida T.
    Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
    [Abstract] [Full Text] [Related]

  • 4. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
    Bracchi P, Zecca E, Brunelli C, Miceli R, Tinè G, Maniezzo M, Lo Dico S, Caputo M, Shkodra M, Caraceni AT.
    Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
    [Abstract] [Full Text] [Related]

  • 5. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
    Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J, Sendo T.
    Biol Pharm Bull; 2015 Sep; 38(12):1850-5. PubMed ID: 26632176
    [Abstract] [Full Text] [Related]

  • 6. Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.
    Hata H, Imamachi K, Ueda M, Matsuzaka M, Hiraga H, Osanai T, Harabayashi T, Fujimoto K, Oizumi S, Takahashi M, Yoshikawa K, Sato J, Yamazaki Y, Kitagawa Y.
    Support Care Cancer; 2022 May; 30(5):4505-4514. PubMed ID: 35113225
    [Abstract] [Full Text] [Related]

  • 7. Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management.
    Tani M, Hatano K, Yoshimura A, Horibe Y, Liu Y, Sassi N, Oka T, Okuda Y, Yamamoto A, Uemura T, Yamamichi G, Ishizuya Y, Yamamoto Y, Kato T, Kawashima A, Nonomura N.
    Sci Rep; 2024 Jun 11; 14(1):13451. PubMed ID: 38862617
    [Abstract] [Full Text] [Related]

  • 8. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
    Soutome S, Hayashida S, Funahara M, Sakamoto Y, Kojima Y, Yanamoto S, Umeda M.
    PLoS One; 2018 Jun 11; 13(7):e0201343. PubMed ID: 30048523
    [Abstract] [Full Text] [Related]

  • 9. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
    Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, Sasaki A.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun 11; 125(6):547-551. PubMed ID: 29574058
    [Abstract] [Full Text] [Related]

  • 10. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.
    Hallmer F, Bjarnadottir O, Götrick B, Malmström P, Andersson G.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Sep 11; 130(3):252-257. PubMed ID: 32536575
    [Abstract] [Full Text] [Related]

  • 11. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V, Campisi G, Bedogni A.
    Support Care Cancer; 2022 Sep 11; 30(9):7047-7051. PubMed ID: 35312858
    [Abstract] [Full Text] [Related]

  • 12. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis.
    Limones A, Sáez-Alcaide LM, Díaz-Parreño SA, Helm A, Bornstein MM, Molinero-Mourelle P.
    Med Oral Patol Oral Cir Bucal; 2020 May 01; 25(3):e326-e336. PubMed ID: 32271321
    [Abstract] [Full Text] [Related]

  • 13. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
    Ehrenstein V, Heide-Jørgensen U, Schiødt M, Akre O, Herlofson BB, Hansen S, Larsson Wexell C, Nørholt SE, Tretli S, Kjellman A, Glennane A, Lowe KA, Sørensen HT.
    Cancer; 2021 Nov 01; 127(21):4050-4058. PubMed ID: 34310704
    [Abstract] [Full Text] [Related]

  • 14. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients.
    Soutome S, Otsuru M, Hayashida S, Murata M, Yanamoto S, Sawada S, Kojima Y, Funahara M, Iwai H, Umeda M, Saito T.
    Sci Rep; 2021 Aug 26; 11(1):17226. PubMed ID: 34446755
    [Abstract] [Full Text] [Related]

  • 15. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA, Liang STY, Sax AZ, Wu K, Yom SK, Huryn JM, Estilo CL.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May 26; 125(5):440-445. PubMed ID: 29580668
    [Abstract] [Full Text] [Related]

  • 16. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B, Drudge-Coates L, Ali S, Pati J, Nargund V, Ali E, Cheng L, Wells P.
    Urol Nurs; 2016 May 26; 36(3):111-6, 154. PubMed ID: 27501591
    [Abstract] [Full Text] [Related]

  • 17. Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
    Chaurand-Lara J, Pacheco-Ruiz L, Trejo-Campos JL, Facio-Umaña JA, Mora-Pérez J.
    Cir Cir; 2019 May 26; 87(4):396-401. PubMed ID: 31264983
    [Abstract] [Full Text] [Related]

  • 18. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
    Wei LY, Kok SH, Lee YC, Chiu WY, Wang JJ, Cheng SJ, Chang HH, Lee JJ.
    J Formos Med Assoc; 2021 Aug 26; 120(8):1572-1580. PubMed ID: 33309430
    [Abstract] [Full Text] [Related]

  • 19. Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw.
    Adachi N, Ayukawa Y, Yasunami N, Furuhashi A, Imai M, Sanda K, Atsuta I, Koyano K.
    Sci Rep; 2020 Mar 27; 10(1):5620. PubMed ID: 32221325
    [Abstract] [Full Text] [Related]

  • 20. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M.
    Cancer Treat Rev; 2018 Sep 27; 69():177-187. PubMed ID: 30055439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.